Mary Caffrey

Advances in radiopharmaceuticals, precision medicine, and the importance of diversity in clinical trials for multiple myeloma and cancer care were among the most popular articles with readers in 2025.

Advancements in 2025 in non-Hodgkin lymphoma treatments focused on bringing CAR T-cell therapy and bispecific antibodies into the community setting.

Linvoseltamab shows promise as a first-line therapy for multiple myeloma, offering high response rates and a simplified treatment approach.

Eunice Wang, MD, highlights breakthroughs in menin inhibitors for acute leukemias, showcasing promising combination therapies and addressing treatment challenges at ASH 2025.

New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, reshaping treatment standards.

A groundbreaking in vivo CAR T-cell therapy shows promise for treating multiple myeloma, potentially revolutionizing cancer care with quicker, safer treatments.

PARADIGM showed azacitidine and venetoclax outperform induction chemotherapy in initial treatment of acute myeloid leukemia (AML).

Epcoritamab combined with rituximab and lenalidomide significantly improves outcomes for relapsed follicular lymphoma, setting a new treatment standard.

A panel at the American Society of Hematology highlights the urgent need for genetic diversity in cancer studies, addressing disparities in treatment outcomes across different ancestries.

Families of children with acute lymphoblastic leukemia face significant financial toxicity, with many experiencing severe economic hardship during treatment.

New trial results reveal fixed-duration venetoclax regimens match continuous ibrutinib therapy in CLL, enhancing patient quality of life and adherence.

Rusfertide shows promise in maintaining hematocrit control and improving quality of life for polycythemia vera patients, reducing phlebotomy needs significantly.

Medicaid expansion has enhanced cancer care in Louisiana, boosting access to treatments like CAR T-cell therapy and improving breast cancer screening initiatives.

The FDA approved epcoritamab with rituximab and lenalidomide for relapsed follicular lymphoma, offering a promising fixed-duration treatment option for patients after their first relapse.

Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival.

A white paper explores how biomarker testing enhances patient outcomes and what barriers prevent access in several common cancers.

Leaders from The US Oncology Network and McKesson discuss how technology can enhance precision medicine and improve patient access to cutting-edge cancer treatments.

Experts discuss strategies for equitable access to genomic testing and cutting-edge therapies for uninsured non-small cell lung cancer patients.

Explore the future of cancer treatment with tumor-agnostic therapies, as experts unveil promising trials and innovative drug developments at ESMO.

A study reveals promising results for combining enfortumab vedotin and pembrolizumab in treating recurrent head and neck cancer, showing a 39% response rate.

IO Biotech's immune-modulatory cancer vaccine combination shows promise in advanced melanoma, despite missing statistical significance for PFS.

New findings reveal that combining Pluvicto with standard therapies significantly improves outcomes for patients with prostate cancer, enhancing quality of life.

Experts at the European Society for Medical Oncology Congress meeting in Berlin, Germany, explore rising cancer rates in young adults, focusing on survivorship challenges and the role of lifestyle interventions in care.

A mini oral session at ESMO of targeted therapy in non-small cell lung cancer included treatments that showed effectiveness in brain metastases.

Experts at ESMO Congress highlighted the urgent need for open discussions on sexual health post cancer treatment, emphasizing its impact on quality of life.